TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

TRACON Pharmaceuticals stock opened at $0.06 on Wednesday. The business’s 50-day moving average price is $0.09 and its 200 day moving average price is $0.62. The firm has a market cap of $197,780.00, a price-to-earnings ratio of 0.02 and a beta of 1.43. TRACON Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The firm had revenue of $0.06 million for the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.